Chan J C, Bartter F C
Pediatrics. 1979 Oct;64(4):488-95.
Growth retardation nearly invariably accompanies hypophosphatemic rickets. Studies were conducted in an adolescent male with this disorder as follows. Protocol I: age, 6 to 16 years; treatment per day, 5,000 to 80,000 units vitamin D2, 1,760 to 2,200 mg phosphorus, orally as buffered phosphate; growth velocity, 5 to 6 cm/year. Protocol II: age 16 to 17 years; treatment per day, 1 alpha,25-dihydroxyvitamin D3, 1 microgram; 2,200 mg of phosphorus, orally as buffered phosphate; growth velocity, 14 cm/year. The height improved from less than third percentile for the decade during study protocol I to the 25th percentile during protocol II. Mineral balance studies showed a reduction of urinary and stool phosphorus during treatment protocol II, while the patient was receiving metabolic diet. The serum phosphorus improved from 2.2 to 4.3 mg/dl and radiologic healing of rickets was documented. No hypercalcemic episode was encountered. The data support the contention that 1 alpha,25-dihydroxyvitamin D3 is the treatment of choice for hypophosphatemic rickets.
生长发育迟缓几乎总是伴随着低磷性佝偻病。针对一名患有这种疾病的青少年男性进行了如下研究。方案一：年龄6至16岁；每日治疗方案为口服5000至80000单位维生素D2以及1760至2200毫克磷（以缓冲磷酸盐形式）；生长速度为每年5至6厘米。方案二：年龄16至17岁；每日治疗方案为口服1微克1α,25 - 二羟维生素D3以及2200毫克磷（以缓冲磷酸盐形式）；生长速度为每年14厘米。身高从方案一研究期间十年内低于第三百分位数提升至方案二期间的第25百分位数。矿物质平衡研究表明，在方案二治疗期间，即患者接受代谢饮食时，尿磷和粪磷减少。血清磷从2.2毫克/分升升至4.3毫克/分升，并且记录到佝偻病的放射学愈合。未出现高钙血症发作。这些数据支持了1α,25 - 二羟维生素D3是低磷性佝偻病首选治疗方法这一观点。
